Cargando…

RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer

BACKGROUND: Currently, the prognosis for metastatic colorectal cancer (mCRC) still remains poor. The management of mCRC has become manifold because of the varied advances in the systemic and topical treatment approaches. For patients with limited number of metastases, radical local therapy plus syst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Kun, Chen, Yajie, Zhang, Zhiyuan, Wu, Ruiyan, Zhou, Menglong, Yang, Wang, Wan, Juefeng, Shen, Lijun, Zhang, Hui, Wang, Yan, Han, Xu, Wang, Jiazhou, Zhang, Zhen, Xia, Fan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568524/ https://www.ncbi.nlm.nih.gov/pubmed/37842200 http://dx.doi.org/10.1093/gastro/goad063

Ejemplares similares

Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer
por: Liu, Shuai, et al.
Publicado: (2022)

Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)
por: Zhao, Wensi, et al.
Publicado: (2023)

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer
por: Song, Yan, et al.
Publicado: (2021)

Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT)
por: Zhou, Shujuan, et al.
Publicado: (2023)

Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E)
por: Chen, Yajie, et al.
Publicado: (2023)

Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer
por: Zhang, Ying, et al.
Publicado: (2019)

TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial
por: Wan, Juefeng, et al.
Publicado: (2023)

Case report: PRES associated with fruquintinib in a patient with metastatic colon cancer
por: Wang, Lu, et al.
Publicado: (2023)

RIFLE is not RIFLE: on the comparability of results
por: Englberger, Lars, et al.
Publicado: (2009)

Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
por: Zhang, Bo, et al.
Publicado: (2022)

Acute aortic dissection caused by fruquintinib for metastatic colorectal cancer—a case report and literature review
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Advances in Radiobiology of Stereotactic Ablative Radiotherapy
por: Qiu, Bin, et al.
Publicado: (2020)

RIFLE is alive: long live RIFLE
por: Ricci, Zaccaria
Publicado: (2012)

Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
por: Peng, Zhi, et al.
Publicado: (2020)

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer
por: Shu, Yefei, et al.
Publicado: (2021)

MRI Radiomics Signature as a Potential Biomarker for Predicting KRAS Status in Locally Advanced Rectal Cancer Patients
por: Zhang, ZhiYuan, et al.
Publicado: (2021)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Is internal target volume accurate for dose evaluation in lung cancer stereotactic body radiotherapy?
por: Peng, Jiayuan, et al.
Publicado: (2016)

Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH)
por: Wang, Yaqi, et al.
Publicado: (2022)

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer
por: Li, Qingli, et al.
Publicado: (2022)

Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer
por: Qin, Shukui, et al.
Publicado: (2021)

PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
por: Zhang, Hong-Qiang, et al.
Publicado: (2022)

Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report
por: Lin, Sen, et al.
Publicado: (2022)

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
por: Gou, Miaomiao, et al.
Publicado: (2022)

Stereotactic Radiotherapy: An Alternative Option for Refractory Ventricular Tachycardia to Drug and Ablation Therapy
por: Shangguan, Wenfeng, et al.
Publicado: (2022)

The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology
por: Finkelstein, Steven Eric, et al.
Publicado: (2011)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

Adrenal oligometastasis cured with stereotactic ablative radiotherapy
por: Malone, Julia, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

An Artificial Intelligence-Based Full-Process Solution for Radiotherapy: A Proof of Concept Study on Rectal Cancer
por: Xia, Xiang, et al.
Publicado: (2021)

Radiomics features on radiotherapy treatment planning CT can predict patient survival in locally advanced rectal cancer patients
por: Wang, Jiazhou, et al.
Publicado: (2019)

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
por: Ye, Dingwei, et al.
Publicado: (2020)

Compraré un rifle
por: Fadanelli, Guillermo J.

Miniature Rifle Shooting
Publicado: (1908)

Safety and Efficacy of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Cancer
por: Wang, Bin, et al.
Publicado: (2022)

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
por: Wang, Lei, et al.
Publicado: (2020)

Comparison of Combination Stereotactic Body Radiotherapy Plus High-Intensity Focused Ultrasound Ablation Versus Stereotactic Body Radiotherapy Alone for Massive Hepatocellular Carcinoma
por: Wang, Lei, et al.
Publicado: (2018)

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
por: Xu, Rui-Hua, et al.
Publicado: (2017)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fn41nu96fvafb7pgc1ltj2esqg